Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: A randomized placebo-controlled study

Circulation

Volumn 110, Issue 8, 2004, Pages 934-939

  Bogaty, Peter ^a   Brophy, James M ^b   Noel, Martin ^a   Boyer, Luce ^a   Simard, Serge ^a   Bertrand, Fernand ^a   Dagenais, Gilles R ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Antiinflammatory agents, nonsteroidal; C reactive protein; Coronary disease; Inflammation; Interleukins

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE B; INTERLEUKIN 6; PADGEM PROTEIN; ROFECOXIB;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LACTONES; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; P-SELECTIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; VASODILATION;

EID: 4344580305     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139338.12464.5F     Document Type: Article

References (39)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
2. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
3. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
4. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
5. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89:425-430.
6. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89:204-209.
7. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481-486.
8. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
9. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation. 1999;99:237-242.
10. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495.
11. Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared to longstanding stable angina. Circulation. 2001;103:3062-3068.
12. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579-1585.
13. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000-1006.
14. Schönbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
15. Baker CSR, Hall RJC, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
16. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
17. Adderley S, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by ERK1/2-mediated induction of cyclooxygenase-2. J Biol Chem. 1999;274:5038-5046.
18. 2-dependent plaque instability. Circulation. 2001;104:921-927.
19. Praticò D, Tillmann C, Zhang Z-B, et al. Acceleration of atherogenesis by COX-1 dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA. 2001;98:3358-3363.
20. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
21. Feng D, Tracy RP, Lipinska I, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis. 2000;9:37-41.
22. Feldmann M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001;37:2036-2041.
23. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-798.
24. Chenevard R, Hurlimann D, Béchir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
25. Title LM, Giddens K, McInemey MM, et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1747-1753.
26. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
27. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-1120.
28. Bogaty P, Dagenais GR, Poirier P, et al. Effect of Atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. Am J Cardiol. 2003;92:1192-1195.
29. Calabró P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-1932.
30. Verma S, Raj SR, Shewchuk L, et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation. 2001;104:2879-2882.
31. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation. 2002;105:2600-2604.
32. Noon JP, Walker BR, Hand MF, Webb DJ. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res. 1998;38:480-484.
33. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-720.
34. Sternik L, Samee S, Schaff HV, et al. C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol. 2002;22:1865-1868.
35. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
36. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet. 1993;341:1496-1500.
37. Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem. 1993;30:373-376.
38. Koenig W, Sund M, Frohlich M, et al. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg Studies, 1984 and 1987. Am J Epidemiol. 2003;158:357-364.
39. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study. Circulation. 2002;106:191-195.